XBiotech Inc (XBIT) - Total Liabilities
Based on the latest financial reports, XBiotech Inc (XBIT) has total liabilities worth $9.73 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
XBiotech Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how XBiotech Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of XBiotech Inc to evaluate short-term liquidity relative to the company's equity base.
XBiotech Inc Competitors by Total Liabilities
The table below lists competitors of XBiotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BioHarvest Sciences Inc. Common Stock
NASDAQ:BHST
|
USA | $22.54 Million |
|
Optex Systems Holdings, Inc. Common Stock
NASDAQ:OPXS
|
USA | $4.56 Billion |
|
Vortex Consolidated Bhd
KLSE:0060
|
Malaysia | RM72.25 Million |
|
Melrose Industries PLC
LSE:MRO
|
UK | GBX4.48 Billion |
|
St. James's Place plc
LSE:STJ
|
UK | GBX223.16 Billion |
|
Transat AT Inc
TO:TRZ
|
Canada | CA$3.54 Billion |
|
Altenergy Acquisition Corp
NASDAQ:AEAE
|
USA | $20.39 Million |
|
Hyundai C&F Inc
KO:227840
|
Korea | ₩71.96 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down XBiotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see XBiotech Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how XBiotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for XBiotech Inc (2012–2025)
The table below shows the annual total liabilities of XBiotech Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.73 Million | -42.16% |
| 2024-12-31 | $16.82 Million | +116.57% |
| 2023-12-31 | $7.77 Million | +36.27% |
| 2022-12-31 | $5.70 Million | -1.57% |
| 2021-12-31 | $5.79 Million | +13.46% |
| 2020-12-31 | $5.11 Million | -91.66% |
| 2019-12-31 | $61.25 Million | +1978.25% |
| 2018-12-31 | $2.95 Million | +4.88% |
| 2017-12-31 | $2.81 Million | -64.81% |
| 2016-12-31 | $7.99 Million | +26.60% |
| 2015-12-31 | $6.31 Million | +100.44% |
| 2014-12-31 | $3.15 Million | +272.43% |
| 2013-12-31 | $845.00K | -22.97% |
| 2012-12-31 | $1.10 Million | -- |
About XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown… Read more